Breaking News Instant updates and real-time market news.

TEVA

Teva

$22.17

0.56 (2.59%)

08:04
08/06/18
08/06
08:04
08/06/18
08:04

Teva says FDA approves Granix injection for indication in pediatric patients

Teva Pharmaceutical Industries announced that the U.S. FDA has approved GRANIX Injection for a new vial presentation and indication in pediatric patients 1 month and older. GRANIX is indicated to reduce the duration of severe neutropenia in adult and pediatric patients 1 month and older with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. The new vial presentation of the product will be available for use in 300mcg/1mL and 480mcg/1.6mL single-dose vials. The prefilled syringe presentations will continue to be available as well. "The new pediatric indication and vial presentation of GRANIX expand the range of treatment options that can be of benefit to both patients and healthcare providers," said Brendan O'Grady, EVP and Head of North America Commercial at Teva. GRANIX was approved by the FDA in August 2012. GRANIX vials are expected to be available in the U.S. shortly.

  • 10

    Sep

  • 16

    Sep

TEVA Teva
$22.17

0.56 (2.59%)

07/18/18
WELS
07/18/18
NO CHANGE
WELS
Novartis report has negative read through for Teva, Mylan, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis (NVS) lowered its 2018 guidance for Sandoz along with its Q2 report and reportedly told Bloomberg that it would consider selling the generic drug unit. He sees a negative read through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL), from Novartis' report, Maris tells investors. He also noted that Novartis said it will not increase prices on its drugs in the U.S. for the rest of 2018, as Pfizer (PFE) recently has also said, calling this "a wise approach and correct read of the increasing intensity of the scrutiny around rising healthcare costs." Maris continues to expect the " chilling effect" on price increases to spread through the industry. Lastly, the analyst pointed out that the Amgen-partnered (AMGN) launch of Aimovig is off to a strong start, which he believes bodes well for Teva's fremanezumab and Eli Lilly's (LLY) galcanezumab.
07/25/18
SBSH
07/25/18
NO CHANGE
SBSH
Buy
Citi opens 'catalyst watch' on Teva ahead of PDUFA date
Citi analyst Liav Abraham opened a "catalyst watch" on Teva Pharmaceutical ahead of the September 16 PDUFA date for fremanezumab for the prophylaxis of episodic and chronic migraine. The analyst has a Buy rating on the shares.
08/02/18
WELS
08/02/18
NO CHANGE
Target $23
WELS
Market Perform
Teva business remains challenged despite Q2 beat, says Wells Fargo
Wells Fargo analyst David Maris Teva delivered "what we had expected," namely a better than consensus Q2 fueled in large part by Copaxone not facing additional generics. However, despite the beat the overall business remains challenged, Maris tells investors. On the earnings call, Teva mentioned that they believe generic pricing the U.S. is improving, but Teva is not experiencing the benefit and expect that things will remain challenging, said Maris, who keeps a Market Perform rating and $23 price target on Teva shares.
08/02/18
WELS
08/02/18
NO CHANGE
WELS
Market Perform
Mylan may have negative read-through from Teva report, says Wells Fargo
Wells Fargo analyst David Maris highlighted some items in Teva's (TEVA) Q2 earnings report and conference call that he believes may have a negative read-through for Mylan (MYL). For one, Teva management said they expect the North American generics environment to remain challenging. Additionally, Copaxone sales were relatively flat sequentially, which would be a negative for Mylan if expectations are for increased contribution from Mylan's Copaxone generic in Q2. Mylan has a large pipeline of biosimilars and Teva mentioned it is building a facility for biosimilars in Germany, which indicates more competition, added Maris, who keeps a Market Perform rating on Mylan shares.

TODAY'S FREE FLY STORIES

ULTI

Ultimate Software

$329.03

-0.76 (-0.23%)

10:52
03/26/19
03/26
10:52
03/26/19
10:52
Downgrade
Ultimate Software rating change  »

Ultimate Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MO

Altria Group

$56.98

0.38 (0.67%)

10:50
03/26/19
03/26
10:50
03/26/19
10:50
Options
At-the-money put buyers in Altria weeklies »

At-the-money put buyers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

CLD

Cloud Peak

$0.16

-0.0022 (-1.35%)

10:48
03/26/19
03/26
10:48
03/26/19
10:48
Hot Stocks
Breaking Hot Stocks news story on Cloud Peak »

Cloud Peak trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:48
03/26/19
03/26
10:48
03/26/19
10:48
Conference/Events
Morgan Stanley IT hard/software analyst to hold analyst/industry conference call »

IT Hardware Analyst…

10:45
03/26/19
03/26
10:45
03/26/19
10:45
General news
Breaking General news story  »

8-Week Bill Announcement…

10:45
03/26/19
03/26
10:45
03/26/19
10:45
General news
Breaking General news story  »

4-Week Bill Announcement…

EYEG

EyeGate

$0.35

-0.035 (-9.09%)

10:42
03/26/19
03/26
10:42
03/26/19
10:42
Hot Stocks
EyeGate ready to move forward with pivotal study after FDA meeting »

EyeGate Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$53.32

0.6 (1.14%)

10:40
03/26/19
03/26
10:40
03/26/19
10:40
Options
3.1K Oracle Jun 50 - Sep 52.5 call spreads bought for 80c »

3.1K Oracle Jun 50 - Sep…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:40
03/26/19
03/26
10:40
03/26/19
10:40
General news
Asia's Export Slump: »

Asia's Export Slump:…

ALDX

Aldeyra

$10.89

3.75 (52.52%)

10:36
03/26/19
03/26
10:36
03/26/19
10:36
Recommendations
Aldeyra analyst commentary at Cantor Fitzgerald »

Aldeyra price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

10:35
03/26/19
03/26
10:35
03/26/19
10:35
General news
Atlanta Fed's Q1 GDPNow estimate was lifted to 1.3% »

Atlanta Fed's Q1…

10:35
03/26/19
03/26
10:35
03/26/19
10:35
General news
U.S. Consumer confidence posted a surprising drop »

U.S. Consumer confidence…

TPX

Tempur Sealy

$57.11

0.9 (1.60%)

10:31
03/26/19
03/26
10:31
03/26/19
10:31
Recommendations
Tempur Sealy analyst commentary at BofA/Merrill »

Tempur Sealy gaining…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENDP

Endo

$8.90

0.635 (7.68%)

10:30
03/26/19
03/26
10:30
03/26/19
10:30
Options
Bullish flow in Endo International as shares gain 9.3% »

Bullish flow in Endo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:30
03/26/19
03/26
10:30
03/26/19
10:30
General news
Fed funds futures are lower »

Fed funds futures are…

LUV

Southwest

$49.19

0.5 (1.03%)

10:29
03/26/19
03/26
10:29
03/26/19
10:29
Hot Stocks
Teamstres material specialists ratify agreement at Southwest »

With over 90% of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRTO

Criteo

$19.24

-2.75 (-12.51%)

, GOOG

Alphabet

$1,195.53

2.81 (0.24%)

10:25
03/26/19
03/26
10:25
03/26/19
10:25
Downgrade
Criteo, Alphabet, Alphabet Class A rating change at Rosenblatt »

Criteo downgraded to…

CRTO

Criteo

$19.24

-2.75 (-12.51%)

GOOG

Alphabet

$1,195.53

2.81 (0.24%)

GOOGL

Alphabet Class A

$1,200.55

3.42 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

10:25
03/26/19
03/26
10:25
03/26/19
10:25
Conference/Events
Morgan Stanley gaming analysts to hold an analyst/industry conference call »

Analysts, along with the…

SYNA

Synaptics

$34.01

1.3 (3.97%)

10:20
03/26/19
03/26
10:20
03/26/19
10:20
Options
Synaptics calls active as shares rally »

Synaptics calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

10:20
03/26/19
03/26
10:20
03/26/19
10:20
General news
U.S. Richmond Fed manufacturing index fell 6 points to 10 in March »

U.S. Richmond Fed…

10:20
03/26/19
03/26
10:20
03/26/19
10:20
General news
Treasury Action: yields continued to recline »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
03/26/19
03/26
10:17
03/26/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
03/26/19
03/26
10:16
03/26/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLPG

Galapagos NV

$96.48

1.25 (1.31%)

10:15
03/26/19
03/26
10:15
03/26/19
10:15
Conference/Events
Galapagos NV management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Apr

  • 26

    Apr

10:15
03/26/19
03/26
10:15
03/26/19
10:15
General news
U.S. consumer confidence dropped back 7.3 points to 124.1 in March »

U.S. consumer confidence…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.